Recursion Pharmaceuticals

Recursion Pharmaceuticals ROE

The Return on Equity (ROE) of Recursion Pharmaceuticals (RXRX) as of Nov 11, 2026 is -57.01 %. In the previous year, Return on Equity (ROE) was -44.81 % — a change of 27.24% (lower).

ROE

-57.01 %

YoY

27.24%

Last updated:

In 2025, Recursion Pharmaceuticals's return on equity (ROE) was -57.01 %, a 27.24% increase from the -44.81 % ROE in the previous year.

The Recursion Pharmaceuticals ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
50.32 USD
Jan 1, 2020
42.18 USD
Jan 1, 2021
-32.80 USD
Jan 1, 2022
-49.28 USD
Jan 1, 2023
-70.79 USD
Jan 1, 2024
-44.81 USD
Jan 1, 2025
-57.01 USD
The Recursion Pharmaceuticals ROE history
YEARROEYoY
-57.01 %+27.24%
-44.81 %-36.70%
-70.79 %+43.64%
-49.28 %+50.26%
-32.80 %-177.76%
42.18 %-16.18%
50.32 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals, Inc. makes money by developing novel therapeutics through its Recursion Operating System (OS), which integrates automation, artificial intelligence, machine learning, and in vivo validation. The company focuses on discovering medicines using advanced technologies in biology, chemistry, automation, and computer science. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964, with REC-994 being an orally bioavailable, superoxide scavenger small molecule for treating cerebral cavernous malformations. The company generates revenue from its platform and clinical development efforts, targeting biopharmaceutical partnerships and potential future drug sales. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, leveraging its Recursion Data Universe to map biological and chemical relationships. The Recursion Operating System (OS) enables the company to rapidly translate silico hypotheses into validated insights and novel chemistry through iterative loops of wet lab biology and chemistry data. The company's platform integrates physical and digital components to create virtuous cycles, driving the discovery of novel therapeutics. Revenue is derived from its technology platform and clinical programs, with potential partnerships in the biopharmaceutical sector. The company's primary products are its Recursion Operating System (OS) and clinical programs such as REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is a small molecule designed for cerebral cavernous malformations, while the other programs are part of its broader therapeutic pipeline. The company targets biopharmaceutical companies and research institutions as potential partners for its technology and drug development services. Recursion Pharmaceuticals, Inc. monetizes its platform through licensing agreements and collaborative research deals, focusing on the discovery of novel medicines using AI-driven approaches. Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

ROE Details

Decoding Recursion Pharmaceuticals's Return on Equity (ROE)

Recursion Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Recursion Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Recursion Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Recursion Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Recursion Pharmaceuticals stock

Return on Equity (ROE) of Recursion Pharmaceuticals is -57.01 % in 2025.

Return on Equity (ROE) of Recursion Pharmaceuticals changed from -44.81 % to -57.01 %, representing a 27.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Recursion Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Recursion Pharmaceuticals

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Recursion Pharmaceuticals